Bleeding Disorders Treatment Market by Type (Fibrin Sealant, Desmopressin, Antibrinolytics, Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates), Drug Class (Von Willebrand Disease, Hemophilia A, Hemophilia B) and by Region Global Trends and Forecast from 2024 to 2030

Published on: Nov 2023
From:USD $3499.00
Number Of Pages:59

Please Choose License Type

Single User

Team User

Corporate License

Request a Sample

INTERESTED IN THIS RESEARCH?

Contact our analysts for inquiries, samples, and expert insights.

Market Size	CAGR	Dominating Region
USD 28.66 billion by 2030	8.3 % CAGR	North America

By Type	By Drug Class
Von Willebrand Disease Hemophilia A Hemophilia B	Fibrin Sealant Desmopressin Antifibrinolytic Recombinant Coagulation Factor Concentrates Plasma Derived Coagulation Factor Concentrates

5/5 - (10 votes)

Bleeding Disorders Treatment Market Overview

The global bleeding disorders treatment market is projected to reach USD 28.66 billion by 2030 from USD 17.29 billion in 2023, at a CAGR of 8.3 % from 2023 to 2030.

Bleeding disorders treatment refers to the interventions and therapies aimed at managing and addressing various types of bleeding disorders. Bleeding disorders encompass a range of conditions characterized by abnormal bleeding or impaired clotting of blood. These disorders can include hemophilia, von Willebrand disease, and rare bleeding disorders. The primary objective of bleeding disorders treatment is to control and prevent excessive bleeding episodes, improve the quality of life for patients, and minimize the associated complications.

Internal and external bleeding diseases can occur. When there is an injury, blood rushes out from the body. Internal bleeding occurs when blood continues to flow beneath the skin, similar to a brain clot. These types of problems occur with bleeding disorders. Haemophilia is one of the most common bleeding disorders in which the blood does not clot. Von Willebrand disease primarily affects women. In general, bleeding disorders therapy involves medications that assist treat and manage the bleeding issue. It may cause dangerous bleeding, blood clotting, and coagulation. The therapy includes new frozen plasma, iron supplements, and antifibrinolytic medications. This bleeding problem can also be caused by a shortage of vitamin K, a reduction in red blood cells, and the use of certain pharmaceuticals that induce negative effects.

Bleeding Disorders Treatment Market | Exactitude Consultancy

The rising incidence of these problems is one of the key drivers of the bleeding disorders treatment industry. The expanding patient population has been aided by genetic predisposition, better diagnostics, and public awareness campaigns. As a result, there is an increasing need for effective therapies to manage and relieve the symptoms of bleeding disorders.

Technological advancements have also played a crucial role in driving market growth. Innovations such as gene therapy, recombinant clotting factors, and novel therapies have revolutionized the treatment landscape. These advancements provide more effective and convenient treatment options for patients, improving their quality of life and reducing the burden of frequent hospital visits. Moreover, the growing demand for personalized medicine has further propelled the market. Bleeding disorders often require tailored treatment approaches due to variations in disease severity and patient response.

High treatment costs remain a significant challenge, particularly for clotting factor replacement therapies and gene therapies. The financial burden posed by these treatments limits access to adequate care, especially in regions with limited healthcare resources. Addressing the cost-effectiveness of treatments and exploring alternative reimbursement models are crucial to ensure equitable access for all patients. Limited availability of treatment options is another restraint in the market. While advancements have been made in managing common bleeding disorders, some rare bleeding disorders still lack effective therapies.

Emerging markets, characterized by rising prevalence and growing healthcare infrastructure, provide unexplored opportunity. Rapid urbanization, increased healthcare expenditures, and cooperation between multinational pharmaceutical corporations and local stakeholders might help solve unmet requirements and broaden market reach. It is also expected to increase due to technological advancements in the research and development of novel medications and therapies for bleeding disorders.

ATTRIBUTE	DETAILS
Study period	2020-2030
Base year	2022
Estimated year	2023
Forecasted year	2023-2029
Historical period	2019-2021
Unit	Value (USD Billion)
Segmentation	By Type, By Drug Class, By Region
By Type	Von Willebrand Disease Hemophilia A Hemophilia B
By Drug Class	Fibrin Sealant Desmopressin Antifibrinolytic Recombinant Coagulation Factor Concentrates Plasma Derived Coagulation Factor Concentrates
By Region	North America Europe Asia Pacific South America MEA

Bleeding Disorders Treatment Market Segment Analysis

The global bleeding disorders treatment market is segmented by drug class, type and region.

Based on drug class, the bleeding disorders treatment market is segmented into fibrin sealant, desmopressin, Antifibrinolytic, recombinant coagulation factor concentrates, plasma derived coagulation factor concentrates. Recombinant coagulation factor concentrates have gained significant traction due to their improved safety profile and wider availability. They are often the treatment of choice for patients with hemophilia or other clotting factor deficiencies. This rise can be attributed to increasing R&D operations and pharmaceutical firms’ greater focus on recombinant products, which has resulted in the introduction of novel drugs. The increased frequency of blood disorders, as well as the growing acceptability of recombinant coagulation factor concentrates, are the primary drivers of the segment. Recombinant coagulation factor concentrates are used in the treatment of diseases such as haemophilia (prevention and management of hemorrhagic episodes).

Bleeding Disorders Treatment Market | Exactitude ConsultancyREPORT OUTLOOK — Bleeding Disorders Treatment Market | Exactitude Consultancy

Based on type, the bleeding disorders treatment market is classified into Von Willebrand Disease, Hemophilia A, Hemophilia B. The haemophilia A category had the biggest market share of 23.01% and was valued at USD 2.48 billion in 2022. Haemophilia A is one of three types of haemophilia, a rare inherited blood disorder. It happens when the blood fails to clot correctly. Haemophilia A mostly affects men and those born with a predisposition to be masculine. It can, however, impact women and those born with a gender proclivity to be feminine.

Haemophilia A, also known as factor VIII deficiency or typical haemophilia, is a genetic disease characterized by a loss or absence of factor VIII, a clotting protein. Haemophilia A is a genetic clotting factor VIII deficiency that causes excessive bleeding in men. It is usually inherited as an X-linked recessive trait, although it can also be caused by spontaneous mutations. In haemophilia A patients, factor VIII medication may be used to treat and stop bleeding.

Bleeding Disorders Treatment Market Players

The global bleeding disorders treatment market key players include Alnylam Pharmaceuticals Inc., CSL Behring (CSL Limited), Johnson & Johnson, Octapharma AG, Sanofi S.A., Wellona Pharma, AbbVie Inc., Grifols S.A., Pfizer Inc., Bayer AG, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S

February. 20, 2023: CSL announced that the European Commission granted HEMGENIX® (etranacogene dezaparvovec) conditional marketing authorization (CMA), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B (congenital Factor IX deficiency) in adults without a history of Factor IX inhibitors.
20 January 2023: Akron Biotechnology, LLC (Akron Biotech), announced it has signed an exclusive global agreement to manufacture virally inactivated Human AB Serum for the cell therapy market using Octaplas®, Octapharma’s pooled, solvent-detergent treated human plasma.

Who Should Buy? Or Key stakeholders

Pharmaceutical Companies
Health Insurance Players
Hospitals
Venture Capitalists
Vendors/Service Providers
Path Labs/Diagnostic Centers
Research and Consulting Firms
Public Hemophilia Foundations and Organizations
Research Institutions
Regulatory Authorities

Bleeding Disorders Treatment Market Regional Analysis

The bleeding disorders treatment market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).

North America: includes the US, Canada, Mexico
Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
South America: includes Brazil, Argentina and Rest of South America
Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA

North America holds the largest share of the worldwide bleeding disorders treatment market during the projection period. Due to the early stage acceptance of new medical technology, the market in this area is experiencing rapid continuous development of pharmaceutical businesses. The United States is expected to dominate the North American market, followed by Canada. Factors such as the high prevalence of bleeding disorders, together with favorable reimbursement and insurance policies, favor the expansion of the bleeding disorders treatment market in the United States. During the projected period, the Canadian bleeding disorder treatment market is predicted to rise at a healthy rate.

Asia Pacific is expected to increase significantly during the forecasted period. Rising healthcare investment in the area is expected to propel the market for the treatment of bleeding disorders. A substantial patient pool also fuels the local market. The market for china bleeding disorders Treatment was valued at USD 0.449 billion in 2021 and is predicted to reach USD 0.769 billion by 2029, growing at a 6.1% CAGR from 2022 to 2029. Since more people are becoming aware of hereditary illnesses, the Chinese market will almost certainly have a sizable revenue share in the market for treating bleeding disorders. The incidence of bleeding disorders among patients is growing, and there are drugs or therapies accessible to treat these illnesses, which is leading the rise in the prevalence of bleeding disorders.

Key Market Segments: Bleeding Disorders Treatment Market

Bleeding Disorders Treatment Market By Type 2020-2030, (USD Billion)

Von Willebrand Disease
Hemophilia A
Hemophilia B

Bleeding Disorders Treatment Market By Drug Class, 2020-2030, (USD Billion)

Fibrin Sealant
Desmopressin
Antifibrinolytic
Recombinant Coagulation Factor Concentrates
Plasma Derived Coagulation Factor Concentrates

Bleeding Disorders Treatment Market By Regions, 2020-2030, (USD Billion)

North America
Europe
Asia Pacific
South America
Middle East and Africa

Important Countries in All Regions Are Covered

Exactitude Consultancy Services Key Objectives:

Increasing sales and market share
Developing new technology
Improving profitability
Entering new markets
Enhancing brand reputation

Key Question Answered

What is the expected growth rate of the bleeding disorders treatment market over the next 7 years?
Who are the major players in the bleeding disorders treatment market and what is their market share?
What are the end-user industries driving demand for market and what is their outlook?
What are the opportunities for growth in emerging markets such as Asia-Pacific, Middle East, and Africa?
How is the economic environment affecting the bleeding disorders treatment market, including factors such as interest rates, inflation, and exchange rates?
What is the expected impact of government policies and regulations on the bleeding disorders treatment market?
What is the current and forecasted size and growth rate of the global bleeding disorders treatment market?
What are the key drivers of growth in the bleeding disorders treatment market?
What are the distribution channels and supply chain dynamics in the bleeding disorders treatment market?
What are the technological advancements and innovations in the bleeding disorders treatment market and their impact on product development and growth?
What are the regulatory considerations and their impact on the market?
What are the challenges faced by players in the bleeding disorders treatment market and how are they addressing these challenges?
What are the opportunities for growth and expansion in the bleeding disorders treatment market?
What are the service offerings and specifications of leading players in the market?

INTRODUCTION
1. MARKET DEFINITION
2. MARKET SEGMENTATION
3. RESEARCH TIMELINES
4. ASSUMPTIONS AND LIMITATIONS
RESEARCH METHODOLOGY
1. DATA MINING
  1. SECONDARY RESEARCH
  2. PRIMARY RESEARCH
  3. SUBJECT-MATTER EXPERTS’ ADVICE
2. QUALITY CHECKS
  1. FINAL REVIEW
3. DATA TRIANGULATION
  1. BOTTOM-UP APPROACH
  2. TOP-DOWN APPROACH
  3. RESEARCH FLOW
4. DATA SOURCES
EXECUTIVE SUMMARY
MARKET OVERVIEW
1. GLOBAL BLEEDING DISORDERS TREATMENT MARKET OUTLOOK
  1. MARKET DRIVERS
  2. MARKET RESTRAINTS
  3. MARKET OPPORTUNITIES
2. IMPACT OF COVID-19 ON BLEEDING DISORDERS TREATMENT MARKET
3. PORTER’S FIVE FORCES MODEL
  1. THREAT FROM NEW ENTRANTS
  2. THREAT FROM SUBSTITUTES
  3. BARGAINING POWER OF SUPPLIERS
  4. BARGAINING POWER OF CUSTOMERS
  5. DEGREE OF COMPETITION
4. INDUSTRY VALUE CHAIN ANALYSIS
GLOBAL BLEEDING DISORDERS TREATMENT MARKET BY TYPE, 2020-2030, (USD BILLION)
1. VON WILLEBRAND DISEASE
2. HEMOPHILIA A
3. HEMOPHILIA B
GLOBAL BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS, 2020-2030, (USD BILLION)
1. FIBRIN SEALANT
2. DESMOPRESSIN
3. ANTIBRINOLYTICS
4. RECOMBINANT COAGULATION FACTOR CONCENTRATES
5. PLASMA DERIVED COAGULATION FACTOR CONCENTRATES
GLOBAL BLEEDING DISORDERS TREATMENT MARKET BY REGION, 2020-2030, (USD BILLION)
1. NORTH AMERICA
  1. US
  2. CANADA
  3. MEXICO
2. SOUTH AMERICA
  1. BRAZIL
  2. ARGENTINA
  3. COLOMBIA
  4. REST OF SOUTH AMERICA
3. EUROPE
  1. GERMANY
  2. UK
  3. FRANCE
  4. ITALY
  5. SPAIN
  6. RUSSIA
  7. REST OF EUROPE
4. ASIA PACIFIC
  1. INDIA
  2. CHINA
  3. JAPAN
  4. SOUTH KOREA
  5. AUSTRALIA
  6. SOUTH-EAST ASIA
  7. REST OF ASIA PACIFIC
5. MIDDLE EAST AND AFRICA
  - UAE
  - SAUDI ARABIA
  - SOUTH AFRICA
  - REST OF MIDDLE EAST AND AFRICA
COMPANY PROFILES*

(BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCT OFFERED, RECENT DEVELOPMENTS)

ROCHE DIAGNOSTICS
QUIDEL CORPORATION
THERMO FISHER SCIENTIFIC INC.
ABBOTT LABORATORIES
HOLOGIC, INC.
BP PLC
BECTON, DICKINSON AND COMPANY
DANAHER CORPORATION
DIASORIN S.P.A.
MERIDIAN BIOSCIENCE, INC.
SEKISUI DIAGNOSTICS LLC
LUMINEX CORPORATION
F. HOFFMANN-LA ROCHE AG
SA SCIENTIFIC LTD *THE COMPANY LIST IS INDICATIVE

LIST OF TABLES

TABLE 1 GLOBAL BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 2 GLOBAL BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 3 GLOBAL BLEEDING DISORDERS TREATMENT MARKET BY REGION (USD BILLION) 2020-2030

TABLE 4 NORTH AMERICA BLEEDING DISORDERS TREATMENT MARKET BY COUNTRY (USD BILLION) 2020-2030

TABLE 5 NORTH AMERICA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 6 NORTH AMERICA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 7 US BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 8 US BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 9 CANADA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 10 CANADA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 11 MEXICO BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 12 MEXICO BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 13 SOUTH AMERICA BLEEDING DISORDERS TREATMENT MARKET BY COUNTRY (USD BILLION) 2020-2030

TABLE 14 SOUTH AMERICA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 15 SOUTH AMERICA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 16 BRAZIL BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 17 BRAZIL BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 18 ARGENTINA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 19 ARGENTINA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 20 COLOMBIA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 21 COLOMBIA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 22 REST OF SOUTH AMERICA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 23 REST OF SOUTH AMERICA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 24 ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET BY COUNTRY (USD BILLION) 2020-2030

TABLE 25 ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 26 ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 27 INDIA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 28 INDIA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 29 CHINA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 30 CHINA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 31 JAPAN BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 32 JAPAN BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 33 SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 34 SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 35 AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 36 AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 37 SOUTH-EAST ASIA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 38 SOUTH-EAST ASIA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 39 REST OF ASIA PACIFIC BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 40 REST OF ASIA PACIFIC BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 41 EUROPE BLEEDING DISORDERS TREATMENT MARKET BY COUNTRY (USD BILLION) 2020-2030

TABLE 42 EUROPE BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 43 EUROPE BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 44 GERMANY BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 45 GERMANY BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 46 UK BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 47 UK BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 48 FRANCE BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 49 FRANCE BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 50 ITALY BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 51 ITALY BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 52 SPAIN BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 53 SPAIN BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 54 RUSSIA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 55 RUSSIA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 56 REST OF EUROPE BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 57 REST OF EUROPE BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 58 MIDDLE EAST AND AFRICA BLEEDING DISORDERS TREATMENT MARKET BY COUNTRY (USD BILLION) 2020-2030

TABLE 59 MIDDLE EAST AND AFRICA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 60 MIDDLE EAST AND AFRICA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 61 UAE BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 62 UAE BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 63 SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 64 SAUDI ARABIA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 65 SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 66 SOUTH AFRICA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

TABLE 67 REST OF MIDDLE EAST AND AFRICA BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

TABLE 68 REST OF MIDDLE EAST AND AFRICA BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

LIST OF FIGURES

FIGURE 1 MARKET DYNAMICS

FIGURE 2 MARKET SEGMENTATION

FIGURE 3 REPORT TIMELINES: YEARS CONSIDERED

FIGURE 4 DATA TRIANGULATION

FIGURE 5 BOTTOM-UP APPROACH

FIGURE 6 TOP-DOWN APPROACH

FIGURE 7 RESEARCH FLOW

FIGURE 8 GLOBAL BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2020-2030

FIGURE 9 GLOBAL BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2020-2030

FIGURE 11 GLOBAL BLEEDING DISORDERS TREATMENT MARKET BY REGION (USD BILLION) 2020-2030

FIGURE 12 PORTER’S FIVE FORCES MODEL

FIGURE 13 GLOBAL BLEEDING DISORDERS TREATMENT MARKET BY TYPE (USD BILLION) 2022

FIGURE 14 GLOBAL BLEEDING DISORDERS TREATMENT MARKET BY DRUG CLASS (USD BILLION) 2022

FIGURE 16 GLOBAL BLEEDING DISORDERS TREATMENT MARKET BY REGION (USD BILLION) 2022

FIGURE 17 MARKET SHARE ANALYSIS

FIGURE 18 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT

FIGURE 19 QUIDEL CORPORATION: COMPANY SNAPSHOT

FIGURE 20 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT

FIGURE 21 ABBOTT LABORATORIES: COMPANY SNAPSHOT

FIGURE 22 HOLOGIC, INC.: COMPANY SNAPSHOT

FIGURE 23 BP PLC: COMPANY SNAPSHOT

FIGURE 24 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT

FIGURE 25 DANAHER CORPORATION: COMPANY SNAPSHOT

FIGURE 26 DIASORIN S.P.A.: COMPANY SNAPSHOT

FIGURE 27 MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT

FIGURE 28 SEKISUI DIAGNOSTICS LLC: COMPANY SNAPSHOT

FIGURE 29 LUMINEX CORPORATION: COMPANY SNAPSHOT

FIGURE 30 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT

FIGURE 31 SA SCIENTIFIC LTD: COMPANY SNAPSHOT

• What is the worth of the bleeding disorders treatment market?

The global bleeding disorders treatment market is projected to reach USD 28.66 billion by 2030 from USD 17.29 billion in 2023, at a CAGR of 8.3 % from 2020 to 2030.

• What is the share of the North America bleeding disorders treatment industry?

• Which are the top companies to hold the market share in the bleeding disorders treatment market?

• What is the CAGR of bleeding disorders treatment market?

The global bleeding disorders treatment market registered a CAGR of 8.3 % from 2023 to 2030.

• What are the key factors driving the market?

The global bleeding disorder market is expected to be driven by the increasing number of diagnosed patients with bleeding disorders across the globe, awareness about bleeding disorder among global population, and government initiatives in developed countries toward the establishment of wide network of diagnosis and treatment centers for bleeding disorders.

In-Depth Database

Our Report’s database covers almost all topics of all regions over the Globe.

Recognised Publishing Sources

Tie ups with top publishers around the globe.

Customer Support

Complete pre and post sales
support.

Safe & Secure

Complete secure payment
process.

INTERESTED IN THIS RESEARCH?

REPORT OUTLOOK

SCOPE OF THE REPORT